Sevelamer in a diabetologist's perspective: A phosphate-binding resin with glucose-lowering potential
Research output: Contribution to journal › Review › Research › peer-review
Sevelamer is a calcium-free and metal-free phosphate-binding oral drug used in the management of hyperphosphataemia in chronic kidney disease. Preclinical and clinical trials have shown glucose and lipid-lowering effects of sevelamer, thereby giving rise to a potential role of the drug in the treatment of patients with type 2 diabetes. These 'novel' effects are most probably derived from the bile acid-binding properties of sevelamer. The proposed potential is supported by the approval of the bile acid sequestrant colesevelam in the United States for the treatment of type 2 diabetes and hypercholesterolaemia. This article offers a brief review on the effects of sevelamer and a perspective on the potential mechanisms behind the glucose-lowering effect of the drug.
Original language | English |
---|---|
Journal | Diabetes, Obesity and Metabolism |
Volume | 17 |
Issue number | 2 |
Pages (from-to) | 116-120 |
Number of pages | 5 |
ISSN | 1462-8902 |
DOIs | |
Publication status | Published - 1 Feb 2015 |
Bibliographical note
Publisher Copyright:
© 2014 John Wiley & Sons Ltd.
- Bile acid sequestrant, Chronic kidney disease, Diabetes, HbA1c, Phosphate resin
Research areas
ID: 305734761